The Drug-Induced Cardiotoxicity Website and App
Frequency - Incidence
Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Sarcoid-like granulomatosis (endo-/extrathoracic)
Publications
El Jammal T, Jamilloux Y, Gerfaud-Valentin M, Richard-Colmant G, Weber E, Bert A, Androdias G, Sève P
Challenging Mimickers in the Diagnosis of Sarcoidosis: A Case Study.
Diagnostics (Basel, Switzerland). 2021;11(7)
Lambert N, Hansen I, El Moussaoui M, Giot JB, Vercheval C, Lommers É, Somja J, Moutschen M, Maquet P
Lung and liver sarcoidosis-like reaction induced by tocilizumab.
British journal of clinical pharmacology. 2021;87(12):4848-4852
Pérez-De-Lis M, Retamozo S, Flores-Chávez A, Kostov B, Perez-Alvarez R, Brito-Zerón P, Ramos-Casals M
Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry).
Expert opinion on drug safety. 2017;16(11):1255-1271
Sarcoidosis induced by tocilizumab: a paradoxical event?
The Journal of rheumatology. 2013;40(10):1773-4